Webinar recap: Boosting recruitment and retention with SDOH ...
As the pharmaceutical industry continues its shift towards more patient-centric models, the incorporation of social determinants of health (SDOH) data has become increasingly valuable.
Metrics for the UK’s VPAG: A work in progress
Just as for previous schemes, metrics are being used to track VPAG, the UK’s voluntary scheme that covers branded medicines pricing and access.
Progress with the UK’s VPAG
Leela Barham looks at the first operational review meeting minutes that have been published on the VPAG, the UK’s latest scheme on branded medicines pricing and access, building on previous
Sarepta pulls plug on Duchenne exon-skipping drug
Sarepta Therapeutics has decided not to continue the development of vesleteplirsen, a follow-up to its Duchenne muscular dystrophy (DMD) therapy Exondys 51.
Blueprint's mastocytosis drug Ayvakit cleared for NHS use
NICE has recommended broad use of Blueprint Medicines' recently-approved therapy for rare blood disorder advanced systemic mastocytosis (ASM) by the NHS in England and Wales, including firs
Featured Content
Latest News
Views & Analysis
Deep Dive
White Papers & Webinar
Podcasts & Video
Partner Content
Welcome to the Molecular Glue Drug Development Summit!
The Molecular Glue Drug Development Summit is back in January, 2025!
Welcome to the 6th RNAi-Based Therapeutics Summit!
RNAi-Based Therapeutics Returns!
EHS&S for Biopharma & Pharma Summit
Implementing Corporate & Regulatory-Guided EHS Practices to Achieve Zero Biosafety, Ergonomic & Chemical Incidents for Employee Safety Across Global Facilities
Europe’s Largest Industry-Led & Dedicated Gathering for mRNA...
The 4th mRNA-Based Therapeutics Summit Europe returns to Frankfurt, Germany as the industry’s premier forum dedicated to showcasing the hottest disease targets,
9th Microbiome Movement Summit Europe
Translating Microbiome R&D into Improved Healthcare Outcomes & Commercial Potential